Pacira BioSciences (PCRX) FY2020 results: revenue $430 million, up 2.0% on the year
Pacira BioSciences, Inc. (PCRX) reported revenue of $430 million for fiscal 2020, the year ended 31 December 2020, up 2.0% on the year before. Net income was $146 million, and diluted earnings per share $3.33. The figures are the company's own, from the 10-K it filed with the SEC on 1 March 2021.
Revenue
$430 million
+2.0% on the year
FY2013FY2020
Operating margin
10.8%
2.5% a year earlier
FY2013FY2020
Net income
$146 million
FY2013FY2020
Diluted EPS
$3.33
FY2013FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
430
421
337
+2.0%
Cost of revenue
117
107
86.8
+9.9%
Gross profit
312
314
250
-0.6%
Gross margin
72.7%
74.7%
74.3%
Research and development
59.4
72.1
55.7
-17.6%
Selling, general and administrative
194
201
177
-3.6%
Operating income
46.4
10.5
15.9
+342.3%
Operating margin
10.8%
2.5%
4.7%
Interest expense
25.7
23.6
21.9
+8.6%
Pre-tax income
20.1
-10.7
-0.4
Income tax
-125
0.3
0.0
Effective tax rate
-624.4%
n/a
n/a
Net income
146
-11.0
-0.5
Net margin
33.9%
-2.6%
-0.1%
Diluted EPS
$3.33
-$0.27
-$0.01
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
77.0
70.5
48.9
+9.2%
Capital expenditure
37.8
10.2
14.5
+272.1%
Free cash flow
39.2
60.4
34.4
-35.0%
Free cash flow margin
9.1%
14.3%
10.2%
Cash from investing
-278
-128
20.6
Cash from financing
222
3.7
9.0
+5,957.3%
Depreciation and amortisation
19.9
19.6
13.2
+1.7%
Share-based compensation
39.9
33.6
31.7
+18.6%
Diluted shares, weighted
44m
42m
41m
+5.2%
Shares outstanding at period end
44m
42m
41m
+4.1%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
620
355
321
+74.6%
Debt
463
306
291
+51.2%
Operating lease liabilities
71.0
40.9
0.0
+73.5%
Other liabilities
121
129
77.5
-6.2%
Total liabilities and equity
1,275
831
689
+53.4%
Fixed assets
137
105
109
+30.6%
Goodwill
99.5
99.5
62.0
0.0%
Intangible assets
96.5
104
0.0
-7.5%
Investments
517
279
277
+85.7%
Cash and equivalents
100.0
78.2
133
+27.8%
Receivables
53.0
47.5
38.0
+11.6%
Inventory
64.7
58.3
48.6
+10.9%
Other assets
207
59.9
22.7
+245.6%
Total assets
1,275
831
689
+53.4%
10-K for the year ended 31 December 2020, filed 1 March 2021: the filing.